Cis-Allosteric Regulation of HIV-1 Reverse Transcriptase by Integrase

Viruses. 2022 Dec 21;15(1):31. doi: 10.3390/v15010031.

Abstract

Reverse transcriptase (RT) and integrase (IN) are encoded tandemly in the pol genes of retroviruses. We reported recently that HIV-1 RT and IN need to be supplied as the pol precursor intermediates, in which RT and IN are in fusion form (RTIN) to exert efficient reverse transcription in the context of HIV-1 replication. The mechanism underlying RTIN's effect, however, remains to be elucidated. In this study, we examined the effect of IN fusion on RT during reverse transcription by an in vitro cell-free assay, using recombinant HIV-1 RTIN (rRTIN). We found that, compared to recombinant RT (rRT), rRTIN generated significantly higher cDNAs under physiological concentrations of dNTPs (less than 10 μM), suggesting increased affinity of RTIN to dNTPs. Importantly, the cleavage of RTIN with HIV-1 protease reduced cDNA levels at a low dose of dNTPs. Similarly, sensitivities against RT inhibitors were significantly altered in RTIN form. Finally, analysis of molecular dynamics simulations of RT and RTIN suggested that IN can influence the structural dynamics of the RT active center and the inhibitor binding pockets in cis. Thus, we demonstrated, for the first time, the cis-allosteric regulatory roles of IN in RT structure and enzymatic activity.

Keywords: HIV-1; deoxyribonucleoside triphosphates; integrase; integration; molecular dynamics; pol; protease; reverse transcriptase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allosteric Regulation
  • HIV Integrase* / metabolism
  • HIV Reverse Transcriptase* / genetics
  • HIV Reverse Transcriptase* / metabolism
  • Reverse Transcriptase Inhibitors / pharmacology

Substances

  • reverse transcriptase, Human immunodeficiency virus 1
  • HIV Reverse Transcriptase
  • Reverse Transcriptase Inhibitors
  • HIV Integrase

Grants and funding

Pl This work was supported by grants from the Japan Agency for Medical Research and Development, AMED (Research Program on HIV/AIDS: JP21fk0410041 and JP22fk0410041 to T.M., O.K. and G.K.) and from JSPS KAKENHI (Grant Number JP20K07525 to T.M.).